US FDA Rejects Lung Cancer Drug

The US Food and Drug Administration has rejected ivonescimab, a lung cancer drug produced by Summit Therapeutics, in a setback to efforts to expand treatment options for patients whose condition worsened after receiving other types of therapy.
The agency noted that a late-stage clinical trial showed ivonescimab significantly delayed disease progression, but taking it did not result in a statistically significant improvement in overall survival.
The decision came after the drug failed to achieve statistically significant results in overall survival, a key measure of long-term treatment benefit, in a late-stage study that formed part of the company's marketing application.
The agency concluded that progression-free survival benefit alone does not tip the benefit-risk balance enough to justify approval.
● Notice to (new) website visitors:You can subscribe to news via WhatsApp for freeClick hereTo get everything new and exclusive.Source akhbaar24